breast cancer

team layoffs workforce
Biotech

Pfizer, Arvinas lose interest in commercializing PROTAC drug

Having already stripped development plans for vepdegestrant on the back of mixed data, Pfizer and Arvinas decided to wash their hands of the drug.
James Waldron Sep 18, 2025 7:35am
An arrow incrementally going up stairs before pointing straight up Blue background

BioNTech's ADC beats Roche’s Kadcyla in breast cancer phase 3

Sep 5, 2025 7:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Celcuity's breast cancer combo hits goals, teeing up FDA filing

Jul 28, 2025 6:00am
oncology cancer test mammogram mammography breast cancer

FDA clears Clairity's 5-year breast cancer risk prediction tool

Jun 5, 2025 1:00pm
blood test vials

Guardant360-guided breast cancer therapy swaps boost survival

Jun 3, 2025 10:00am
On target clinical trial success bullseye score

AstraZeneca's breast cancer pill boosts PFS by 56% in phase 3

Jun 2, 2025 7:10am